Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack

Structured PICO

Does CYP2C19 loss-of-function allele carrier status increase the risk of stroke and composite vascular events in patients with ischemic stroke or TIA treated with clopidogrel?

Population

Patients with ischemic stroke or transient ischemic attack (TIA) treated with clopidogrel

Intervention

Clopidogrel therapy in carriers of CYP2C19 loss-of-function alleles

Comparator

Clopidogrel therapy in noncarriers of CYP2C19 loss-of-function alleles

Outcome

Stroke and composite vascular eventscomposite

CYP2C19 loss-of-function allele carriers have reduced clopidogrel efficacy, leading to a higher risk of recurrent stroke and vascular events after an ischemic stroke or TIA.

Abstract

Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events than noncarriers among patients with ischemic stroke or TIA treated with clopidogrel.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Pan et al. (Thu,) studied this question.

synapsesocial.com/papers/69da216d0d540cafc58386b0 https://doi.org/https://doi.org/10.1161/circulationaha.116.024913

Bookmark

View Full Paper